Biotech Damian Garde and Adam Feuerstein STAT Plus: Biogen CEO: Company was ‘wrong’ about initial Aduhelm price, ‘courageous’ to lower it
Biotech Adam Feuerstein STAT Plus: FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T treatment
Biotech Matthew Herper and Megan Molteni STAT Plus: Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions
Biotech Matthew Herper and Megan Molteni STAT Plus: Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
Don't Miss STAT Staff STAT Plus: A preview of the burning biotech and health tech questions at JPM 2022
Biotech Angus Chen STAT Plus: A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
Health Tech Mohana Ravindranath STAT Plus: Telehealth companies are testing the waters with taking on more risk
Biotech Adam Feuerstein STAT Plus: Sarepta’s Duchenne gene therapy improves muscle function but debate lingers